TNFSF13 and autoimmune disease: Other drugs targeting B cells are also tested in autoimmune diseases such as the depleting antibody ianalumab targeting the BAFF-R, the negatively signaling epratuzumab targeting CD22, and atacicept a soluble form of the TACI receptor antagonizing BAFF and the related member from the TNF superfamily a proliferation inducing ligand (APRIL, TNFSF13) (11–13).